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Molecular genetic technology is diffusing from the research laboratory to the clinical
laboratory, where it has already begun to influence prenatal diagnosis and counseling. In the
very near future, this technology will be applied more generally, using population-based
screening strategies. Pilot programs are beginning to evaluate the technical feasibility and
efficacy ofrecombinant DNAtechniques for newborn screening follow-up. DNA-based popula-
tion screening is being considered for heterozygous carriers of an autosomal recessive disorder
such as cystic fibrosis in order to identify carrier couples at risk of having an affected child. We
will review the current DNA methodologies in the context ofthree genetic disorders: sickle-cell
disease, Duchenne muscular dystrophy, and cystic fibrosis. We will then consider the require-
ments for implementation of these new technologies. We will conclude that implementation
will require two key factors: machines and people. Machines are required to automate
molecular genetic procedures, which are currently personnel-intensive, so that the expense can
be reduced and the procedures made more cost-effective. The people who are required are
health professionals knowledgeable in the clinical aspects of the target disorders, as well as in
the DNA laboratory testing. These professionals will be able to facilitate sample acquisition
and information exchange among the laboratory, the primary health care provider, and the
families requesting consultation.
One of the primary goals of basic research in human genetics is to improve our
understanding of the underlying molecular mechanisms responsible for human
disease. The recent explosion of information in this area has provided medical
genetics with the opportunity to achieve improved diagnosis ofpatients affectedwith
genetic diseases and improved ascertainment ofindividuals heterozygous for autoso-
mal recessive disorders.
We will review three genetic disorders, sickle-cell disease (SCD), Duchenne
musculardystrophy (DMD), and cysticfibrosis (CF), and discuss the recent advances
in molecular genetic technology as they relate to screening and diagnosis for these
diseases. The application ofthe techniques ofmolecular biology to neonatal screen-
ing relies on our ability to manipulate DNA from dried blood specimens on filter
paper blotters. These blotters, frequently referred to as "Guthrie cards" after their
originator, Dr. Robert Guthrie, have proven theirvalue in newborn screening due to
ease of sample collection and transport and to stability of avariety of analytes [1-3].
Examples of analytes routinely analyzed from Guthrie cards include phenylalanine
for detection of phenylketonuria (PKU), thyroxine (T4) and thyroid stimulating
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hormone (TSH) for congenital hypothyroidism, and hemoglobin for sickle-cell
disease and other hemoglobinopathies. The illustrations which we will provide will
demonstrate that DNA is another analyte which can be analyzed, using these dried
blood specimens. In addition, we will consider the requirements for implementation
of this molecular genetic technology so that it may have an even broader effect in
clinical medicine.
SICKLE-CELL DISEASE
Sickle-cell disease is a common genetic disorder occurring with an incidence of 1 in
400 births among individuals in the U.S. of African-American origin [3]. Universal
newborn screening for sickle-cell disease was recommended by an NIH Consensus
Development Conference [4], because of the evidence that prophylactic treatment
with penicillin is effective in preventing the infant mortality associated with this
disorder [5].
Knowledge of sickle-cell disease has consistently been at the forefront in our
understanding of the molecular pathogenesis of human disease, and this phenome-
non has been true also in the area of molecular genetic diagnosis. In 1978, Kan and
Dozy demonstrated the use of a restriction fragment length polymorphism (RFLP)
for the prenatal diagnosis of sickle-cell disease [6,7]. They showed that there was
linkage disequilibrium between the sickle-cell mutation and a 13 kb HpaI restriction
fragment: 87 percent of individuals with the hemoglobin S allele had this restriction
fragment. This fragment was, however, only a linked marker for the sickle-cell
mutation; it required knowledge of the RFLP pattern of the proband and was not
informative in all families. In 1982, it was shown that the sickle-cell mutation resulted
in an alteration in the restriction recognition sequence for MstII [8,9]. Detection of
the presence or absence of this restriction site by MstII digestion provided a sensitive
and specific DNA test which did not require analysis of other family members and
would identify all individuals with thePs allele. In 1983, Conner et al. utilized
allele-specific oligonucleotide (ASO) probes for detection of the P allele by differen-
tial hybridization [10]. By controlling the conditions of hybridization and washing,
the presence of the PA and/orBs alleles could be determined with the appropriate
labeled ASOs hybridized to Southern blots [11]. Electrophoresis of the human DNA
was required to separate the specific diagnostic band from other cross-hybridizing
sequences [10].
In 1985, Saiki et al. described the polymerase chain reaction (PCR) and demon-
strated the application of this new enzymatic amplification technique for the
diagnosis of sickle-cell disease [12]. This methodology permitted amplification of a
specific DNA region of interest, such as that spanning the sickle-cell mutation in the ,-globin gene. There would be approximately 220,000-fold enrichment in the region
ofinterest at the end of 20 PCR cycles with 85 percent efficiency of amplification per
cycle. This process resulted in marked diminution of the cross-hybridization that had
previously been observed using ASOs, since now the amplified region of interest
represented the majority
of the DNA present.
This process permitted to
hybridize the ASOs directly to dot blots of the PCR reaction products or, alterna-
tively, to separate the PCR reaction products on a gel and stain directly with
ethidium bromide. The diagnostic application of PCR was facilitated by the introduc-
tion of a thermostable (Taq) DNA polymerase which permitted automation of this
process [13].
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Our group had been interested in the analysis of DNA on the dried blood
specimens used for newborn screening [14]. PCR amplification of microextracted
DNA from the specimens facilitated genotypic analysis of SCD [15,16]. One could
successfully distinguish AA homozygotes, SA heterozygotes, and SS homozygotes
usingASO probes labeledwith 32P [15] orhorseradishperoxidase (HRP) [17], aswell
as by direct ethidium bromide staining ofgels after digestionwith restriction enzyme
[16,18]. Chehab and Kan recently presented an elegant fluorescence assay for
detection ofthe sickle-cell mutation which readily lends itselfto automation [19].
We have proposed that DNA follow-up to newborn screening would permit rapid
genotypic confirmation ofpositive newborn screening specimens and clarification of
thosewhich were questionable after the initial protein-based evaluation [15]. We are
currently involved in a project, in collaboration with the newborn screening labora-
tory in the Texas Department of Health, to evaluate this approach. Preliminary
results indicate that PCR-based strategies can be effective in providing genotypic
confirmation and clarification with a very low recall rate for second specimens [18].
Such an approach would reduce one of the major expenditures for newborn screen-
ing programs, the personnel time required to contact the families to obtain the con-
firmatory liquid blood specimens [15]. In addition, we feel that contacting the family
in a more timely fashion with the knowledge of the genotype would convey to them
the appropriate sense ofurgency and immediacy regardingthe diagnosis ofSCD and
might reduce the frequency ofnoncompliance with antibiotic prophylaxis [15].
DUCHENNE MUSCULAR DYSTROPHY
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder with
incidence estimatesof1:3,000 to 1:5,000male live births or 1:11,500overallbirths [3].
This disorder is characterized by progressive deterioration of the muscles, resulting
in death in the second or third decade. Recent advances in the cloning and
characterization ofmutations in the DMD locus at Xp2l have improved remarkably
the diagnostic capability for this disorder [20,21]. Utilizing the DMD cDNA probes,
approximately56 percent ofpatients reveal detectable deletions [21]. Because ofthe
frequency of deletions, this disorder is particularly amenable to rapid diagnosis by
PCR, since deletions which remove one or both of the priming sites would prevent
amplification. Multiplex PCR permits the amplification of many sequences simulta-
neously and results in detection of 80 percent to 90 percent of all DMD gene
deletions [22,23]. Thus, utilizing nine sets ofPCRprimers, thevast majorityofDMD
deletions can be detected, and nearly 50 percent of all DMD patients will have a
recognizable deletion. This procedure greatly facilitates the diagnosis of these
patients and in manycases can replacebiopsyconfirmationofthe DMD diagnosis. In
the DNA laboratory, multiplex PCR replaces the personnel-intensive efforts re-
quired to perform Southern blotting with multiple probes. Multiplex PCR should
accelerate implementation of DNAtechnology for diagnosis ofDMD in the general
medical community and would facilitate rapid genotypic confirmation in at least 50
percent ofpatients ascertained by infant screening programs for DMD.
CYSTIC FIBROSIS
Cystic fibrosis is an autosomal recessive disorderwith an average incidence among
Caucasians of 1:2,000 births and a heterozygote frequency of approximately 1:22
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individuals [3]. Death usually results in the second to fourth decades from obstruc-
tive pulmonary disease and infection.
In September of1989,we received the excitingnewsthatthe geneforcysticfibrosis
(CF) had been cloned and the mutation determined [24-26]. The common Cauca-
sian CF mutation is referred to as AF508, because it results in the loss of three
nucleotides in frame and, consequently, the deletion of a phenylalanine residue,
amino acid 508, in the CF protein. Knowledge of this mutation permitted PCR
amplification and hybridization with ASOs for analysis ofthe presence or absence of
the AF508 mutation among homozygotes and heterozygotes for this disorder [27].
The AF508 mutation was present on 75.8 percent of the CF chromosomes. The
results of this analysis indicated that population-based screening would identify
approximately 57 percent ofthe non-Ashkenazic white couples at risk for CF [27]. A
recent NIH-sponsored workshop recommended that, at this time, population-based
carrier screening should not be undertaken and that mutation analysis should be
used in families onlywhere there was an affected individual with this disorder [28].
Pilot studies on the efficacy ofnewborn screening for cysticfibrosis are in progress
[3]. Although reports of PCR amplification for detection of the AF508 mutation in
dried blood specimens are not yet available, such samples have been used for
haplotype analysis in this disorder. In one remarkable example from the United
Kingdom, a specimen that had been stored for 17 years was obtained for amplifica-
tion and restriction enzyme digestion [29]; the specimen, obtained in 1971 and
analyzed in 1988, permitted informed genetic counseling for the sibling of that
deceased patient with CF. This experience showed that such newborn screening
specimens can be quitevaluable as amolecular genetic resource. It also showed that,
in addition to providing a simple form of sample acquisition and transport, dried
blood specimens on filter paper blotters also provide a convenient medium for
storage ofDNA in a stable form.
IMPLEMENTATION OF MOLECULAR GENETIC TECHNOLOGY
FOR THE FUTURE
The key to implementation and broad-ranging diffusion of this technology will be
twofold: machines and people. Automated equipment is essential in order to reduce
the current labor-intensive molecular genetic techniques. In our current trials to
interface recombinant DNAmethodologies with newborn screening, the major costs
are the salaries of the technical personnel who perform the DNA microextractions
and analyses. The ability to automate this technology would make it available at an
acceptable cost. In addition, equipment automation will reduce personnel involve-
ment in the repetitive manipulations associated with these procedures, in turn
decreasing the opportunity for human error [30]. Just as there is the need for quality
assurance and quality control in other aspects of neonatal screening [31,32], there
alsowill be the need foranalogous standards tobe adopted for the moleculargenetic
components ofsuch programs.
But, having said that we should automate in order to reduce personnel costs and
human error, why have I said that the second important factor in implementation of
this technologyispeople? Thepeople who are needed are individualsknowledgeable
in both the clinical sector and the DNA laboratory, who are able to operate at the
interface ofthese two arenas. These healthprofessionalswill facilitate the movement
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of samples to the DNA laboratory and will ensure that the information from the
laboratory is transferred to the physician and the patient in a clear, effective manner.
In summary, the successful implementation of this technology will require re-
search and innovation. Research will be required in order to provide automated and
reliable methods. Innovation will be required in order to introduce this novel
technology effectively and to train the health professionals who will facilitate
implementation ofmolecular genetic technologies for improved patient care.
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